|Bid||4.3000 x 900|
|Ask||4.3200 x 900|
|Day's Range||4.2500 - 4.4100|
|52 Week Range||3.4600 - 13.0000|
|Beta (5Y Monthly)||0.83|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2021 - May 17, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.00|
Biocept Provides Update on COVID-19 Testing with More than 350,000 Samples Received to Date
Biocept, Inc. (Nasdaq: BIOC) will host a webinar featuring leading neuro-oncologists to discuss the use of the Company’s proprietary cerebrospinal fluid (CSF) assay for diagnosing and managing tumors that have metastasized to the central nervous system (CNS), including the brain or spinal column. Biocept’s CSF assay provides enhanced sensitivity compared with CSF cytology, the current standard of care, and has the added advantage of identifying actionable molecular targets for use in treatment decisions while providing quantitative information needed for assessing treatment response and monitoring disease progression.
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 49,040 shares of its common stock to eight new employees. These inducement stock options have a grant date of March 31, 2021, and were granted as inducements material to the new employees entering into employment with Biocept in accordance with Nasdaq Listing Rule 5635(c)(4).